A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case–control study of 410 patients with 8 years post-operative follow-up
Top Cited Papers
- 12 February 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in Acta Neuropathologica
- Vol. 126 (1), 123-135
- https://doi.org/10.1007/s00401-013-1084-y
Abstract
Pituitary adenomas are currently classified by histological, immunocytochemical and numerous ultrastructural characteristics lacking unequivocal prognostic correlations. We investigated the prognostic value of a new clinicopathological classification with grades based on invasion and proliferation. This retrospective multicentric case–control study comprised 410 patients who had surgery for a pituitary tumour with long-term follow-up. Using pituitary magnetic resonance imaging for diagnosis of cavernous or sphenoid sinus invasion, immunocytochemistry, markers of the cell cycle (Ki-67, mitoses) and p53, tumours were classified according to size (micro, macro and giant), type (PRL, GH, FSH/LH, ACTH and TSH) and grade (grade 1a: non-invasive, 1b: non-invasive and proliferative, 2a: invasive, 2b: invasive and proliferative, and 3: metastatic). The association between patient status at 8-year follow-up and age, sex, and classification was evaluated by two multivariate analyses assessing disease- or recurrence/progression-free status. At 8 years after surgery, 195 patients were disease-free (controls) and 215 patients were not (cases). In 125 of the cases the tumours had recurred or progressed. Analyses of disease-free and recurrence/progression-free status revealed the significant prognostic value ( < 0.001; < 0.05) of age, tumour type, and grade across all tumour types and for each tumour type. Invasive and proliferative tumours (grade 2b) had a poor prognosis with an increased probability of tumour persistence or progression of 25- or 12-fold, respectively, as compared to non-invasive tumours (grade 1a). This new, easy to use clinicopathological classification of pituitary endocrine tumours has demonstrated its prognostic worth by strongly predicting the probability of post-operative complete remission or tumour progression and so could help clinicians choose the best post-operative therapy.Keywords
This publication has 52 references indexed in Scilit:
- Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatmentClinical Endocrinology, 2012
- Endothelial Expression of Endocan Is Strongly Associated with Tumor Progression in Pituitary AdenomaBrain Pathology, 2012
- Pituitary Carcinoma: Difficult Diagnosis and TreatmentJournal of Clinical Endocrinology & Metabolism, 2011
- Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysisPituitary, 2011
- Giant Pituitary AdenomasThe American Journal of Surgical Pathology, 2011
- Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT statusEuropean Journal of Clinical Investigation, 2011
- Proliferation markers of human pituitary tumors: Contribution of a genome-wide transcriptome approachMolecular and Cellular Endocrinology, 2010
- Clinical Tumor Growth and Comparison with Proliferation Markers in Non-functioning (Inactive) Pituitary AdenomasExperimental and Clinical Endocrinology & Diabetes, 2007
- TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading systemVirchows Archiv, 2006
- Silent Adenoma Subtype 3 of the Pituitary—Immunohistochemical and Ultrastructural Classification: A Review of 29 CasesUltrastructural Pathology, 2005